Glioma Tumors - Symptoms and Clinical Trials

What is A Glioma Brain Tumor?

Gliomas are ‘primary’ brain tumors, which means they are derived from the brain tissue itself. Common subtypes include astrocytoma, oligodendroglioma, glioblastoma, and gliosarcoma. All gliomas are graded based upon World Health Organization (WHO) criteria:

Grade I: Slow-growing tumor cells; almost normal appearance; least aggressive 
Grade II: Relatively slow-growing cells; slightly abnormal appearance; can invade nearby tissue; may recur as a higher-grade tumor 
Grade III: Faster-dividing cells; abnormal appearance; infiltrates normal tissue 
Grade IV: Rapidly-dividing and abnormal cells; contains necrotic areas of nonviable tissue

Grade II, III, and IV gliomas are most common in adults. Grade IV gliomas (known as glioblastomas or gliosarcomas) are the most common primary brain cancer in adults. Glioblastoma is a rapidly growing tumor that can occur at any age, but its incidence increases with advanced age. Grades I, II, and III gliomas are less aggressive and often seen in younger populations, yet can still recur and defy conventional therapies. All gliomas cause symptoms through a combination of mass effect on the surrounding brain and direct infiltration of the brain tissue.

A primary focus of the Ivy Brain Tumor Center is gliomas.

Grade II, III, and IV gliomas are most common in adults. Grade IV gliomas (known as glioblastomas or gliosarcomas) are the most common primary brain cancer in adults. For this reason, our clinical trials cover all grades and subtypes of adult gliomas.


Brain tumor symptoms vary widely depending on the type, location, size, and growth rate of the tumor. There are no specific symptoms that only occur due to a brain tumor.

General symptoms of brain tumors include:

  • New onset or change in pattern of headaches
  • Headaches that gradually become more frequent and more severe
  • New onset of seizures
  • Gradual loss of sensation or movement in an arm or a leg
  • Difficulty with balance
  • Difficulty speaking
  • Personality or behavior changes
  • Confusion
  • Unexplained nausea or vomiting
  • Blurred vision, double vision, or loss of peripheral vision
  • Hearing problems

Contact a medical professional if you are experiencing any symptoms.

Advanced Phase 0/2 Clinical Trials

The Ivy Brain Tumor Center is home to the largest Phase 0/2 clinical trials program for brain tumor patients in the world. Our studies select patients with specific genetic signatures to receive a single dose of a matched experimental regimen a day prior to their previously-planned brain tumor operation. Instead of placing all our hopes on a single drug, our trials emphasize combined-agent approaches that recognize the inherent complexities, and resistance mechanisms, of brain tumors. At the time of surgery, tissue samples are rapidly collected and then tested in our laboratories using an array of highly-sensitive molecular and pharmacological technologies. Within days of surgery, our Phase 0/2 team identifies which investigational therapies have successfully penetrated the patient’s tumor and whether these agents have also effectively modulated the tumor’s biology. Once the experimental regimen proves its ability to reach its target and undermine the tumor’s core programming, then the patient is ‘graduated’ to this chosen regimen at maximum therapeutic doses. Now, the tumor is finally under siege.

Phase 0/2 patients who are graduated to therapeutic dosing will have the confidence of knowing that their tailored treatment regimen is based upon direct evidence of their individual tumor’s responsiveness. Conversely, Phase 0/2 studies also identify which specific strategies will not work for individual patients and tumors. This critical information spares patients from investing their precious time, effort, and energy in futile therapies that will not meet their needs. Because of the unprecedented speed with which our analysis is completed, our Phase 0/2 trial patients do not lose any opportunity to pursue other avenues for treatment at any center, including any other clinical trial, after surgery. We understand that time is the most important commodity for brain tumor patients and our clinical trials stand apart from conventional studies that routinely take months to inform patients that a therapy is ineffective.

Phase 0/2 studies are not synonymous with first-in-human studies. While some of our experimental agents are being tested in patients for the first time ever, many more of our clinical trials consist of new agents and new combinations of agents that are proven safe in patients, but have never been trialed as a therapy for brain tumors. Without exception, the Ivy Brain Tumor Center and its investigators have no financial or proprietary interest in any agent in our clinical trials. 

Trial Screening Requests

For brain tumor patients facing the fight of their lives, no stone should be left unturned. Our clinical investigators treat more brain tumor patients than any hospital in the nation and the Ivy Brain Tumor Center’s portfolio of early-phase clinical trials serves as a resource for the world’s brain tumor community. Within 36 hours of a trial screening request, our team assesses a patient’s suitability for our clinical trials program, as well as provides additional support to the physicians managing these cases. Patients enrolled in our studies are not required to transfer their care to our center, as our philosophy is to partner with, not replace, their treatment team. 

Trial Screening Requests are provided at no cost and, for patients we determine to be eligible for a clinical trial, the Ivy Brain Tumor Center covers all costs associated with study participation.

Close Menu